Fundamental Data for BMRN

BIOMARIN P(NSDQ:BMRN)

BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin''s lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.

# Employees: 649

Address: 105 Digital Drive,Novato,CA,USA

Phone: 415 506-6700

Fax: 415 382-7889

Website: www.biomarinpharm.com

Email: IR@BMRN.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Pierre Lapalme (Chmn.; Dir.)

Jean Jacques Bienaime (C.E.O.)

Jeffrey H. Cooper (Sr. V.P.; C.F.O.)

Elaine Heron (Dir.)

Joseph Klein III (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/17/2010

Mean EPS (Next Qtr): $0.00

Mean EPS (Year): ($0.06)

Mean Estimate(Long Term): $33.08

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 17

Shares Performance

Period	BMRN	Compare to S&P
YTD	-4.66 %	-21.10 %
4 Weeks	-0.18 %	-1.25 %
12 Weeks	3.04 %	-2.86 %

Shares Information

Analyst Coverage: Y

Avg Volume: 1319973

Shares Outstanding: 100M

Market Cap: $1.70B

52 Week High: $20.83

52 Week Low: $10.14

P/E Ratio: 99.820

PEG Ratio: -0.010

Split: On 1/1/1990 BMRN split by factor of 0.100

Earnings Performance

EPS Growth in Last Quarter: -0.01 %

EPS Growth in Last Year: 500.00 %

Sales Growth in Last Quarter: -2.39 %

Sales Growth in Last Quarter: 11.23 %

Financials

Qtr Book Value: $5.60

Cash Flow/Share: $37.06

Change in Payout Ratio: 0.000

Price/Sales: 5.050